A5085102151- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Lipoproteins and Cardiovascular Health
- Cardiac, Anesthesia and Surgical Outcomes
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Peripheral Artery Disease Management
- Adipokines, Inflammation, and Metabolic Diseases
- Cardiovascular Function and Risk Factors
- Diabetes Treatment and Management
- Cardiac Valve Diseases and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Cardiac and Coronary Surgery Techniques
- Renal and Vascular Pathologies
- Metabolism, Diabetes, and Cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Aortic aneurysm repair treatments
- Cerebrovascular and Carotid Artery Diseases
- Acute Kidney Injury Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Heart Failure Treatment and Management
Icahn School of Medicine at Mount Sinai
2023-2025
Humanitas University
2021-2025
Mount Sinai Hospital
2024-2025
Cardiovascular Institute of the South
2023-2025
Humanitas Gavazzeni
2024
IRCCS Humanitas Research Hospital
2021-2024
Policlinico Tor Vergata
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Casa di Cura Columbus
2022
University of Naples Federico II
2021
To appraise all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute syndrome in two network meta-analyses.Forty-three (N = 189 261 patients) trials and 19 139 086 beyond were included for efficacy/safety endpoints appraisal. Within months, ticagrelor 90 mg bis die (b.i.d.) [hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.49-0.88], aspirin (HR, 0.85; CI, 0.76-0.95), aspirin, clopidogrel rivaroxaban 2.5 b.i.d. 0.51-0.86) the...
Abstract Antithrombotic therapy represents the cornerstone of pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration antithrombotic is still matter debate requiring a critical assessment patient comorbidities, clinical presentation, revascularization modality, and/or optimization medical treatment. 2023 European Society Cardiology (ESC) guidelines for management ACS encompassing both without ST segment elevation have been recently...
Drug-coated balloons (DCB) are an emerging tool for modern percutaneous coronary intervention (PCI), but evidence on their use de novo lesions large vessels is limited.
Background: Dual antiplatelet therapy (DAPT) with a potent P2Y 12 Inhibitor coupled aspirin for 1 year is the recommended treatment patients acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Alternatively, monotherapy inhibitor after short period of DAPT has emerged as bleeding reduction strategy. Methods: We pooled individual patient data from randomized trials that included ACS PCI treated an initial 3-month course followed by ticagrelor versus continued plus...
ABSTRACT Background Limited data exist on the impact of polyvascular disease (PolyVD) clinical outcomes in female patients undergoing transcatheter aortic valve replacement (TAVR). We therefore sought to investigate women with versus without PolyVD TAVR. Methods Female participants from multicentre Women's International Transcatheter Aortic Valve Implantation (WIN‐TAVI) registry were categorized based presence or absence PolyVD. The population was defined as atherosclerotic affecting ≥ 2...
Identifying alternative contributors to the residual risk of atherosclerotic cardiovascular disease (ASCVD) beyond LDL cholesterol (LDL-C) levels is crucial. We investigated relative impact triglycerides (TGs) and high-sensitivity C-reactive protein (hs-CRP) on outcomes in statin-treated patients with well-controlled LDL-C undergoing percutaneous coronary intervention (PCI) for established ASCVD. included 9446 < 70 mg/dL PCI between 2012 2022, stratified into four groups: (i) no (TG <150 +...
Background The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with adverse cardiovascular outcomes. However, limited evidence exists regarding its prognostic role in patients diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI), which we sought to explore this analysis. Methods We retrospectively evaluated all PCI at large tertiary centre between 2012 and 2022. Patients were stratified according the presence DM, NLR quartiles...